Important Information for Regeneron Pharmaceuticals Investors: Rosen Law Firm Announces Class Action Lawsuit
NEW YORK, March 04, 2025
Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (Regeneron) (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. The lawsuit alleges that Regeneron and certain of its officers and directors violated the Securities Exchange Act of 1934 by making materially false and misleading statements and omitting material information during the Class Period.
Background
Regeneron is a biotechnology company that develops and commercializes medicines for various diseases. The company is well-known for its Eylea® (aflibercept) injection for the treatment of wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Allegations
The complaint alleges that Regeneron and its executives made false and misleading statements and omitted material information about the clinical trial data for Eylea in the treatment of wAMD. Specifically, the complaint alleges that Regeneron and its executives:
- Overstated the efficacy of Eylea in the treatment of wAMD
- Downplayed the risks associated with Eylea
- Failed to disclose that the clinical trial data for Eylea in wAMD did not meet the primary endpoint
As a result of this alleged misconduct, Regeneron’s stock price was artificially inflated during the Class Period.
Impact on Individual Investors
If you purchased Regeneron securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is fast approaching, so it’s important to act quickly if you believe you may be eligible to participate in the lawsuit. You may also wish to consult with a securities attorney to discuss your options.
Impact on the World
The allegations against Regeneron have significant implications for the biotech industry as a whole. The lawsuit highlights the importance of transparency and accuracy in clinical trial reporting. It also underscores the need for investors to be vigilant in their research and due diligence when investing in biotech companies.
Conclusion
If you purchased Regeneron securities during the Class Period and believe you may be entitled to compensation, it’s important to act quickly. The lead plaintiff deadline is fast approaching, and the experienced securities attorneys at Rosen Law Firm can help you evaluate your options. The allegations against Regeneron also serve as a reminder of the importance of transparency and accuracy in clinical trial reporting, and the need for investors to be diligent in their research.
For more information, please contact the Rosen Law Firm at (866) 767-3653 or via email at [email protected]. You can also visit the firm’s website at www.rosenlegal.com.com/cases-registeron-pharmaceuticals-inc-regn-class-action-lawsuit-sec.html
This notice does not constitute an offer or solicitation of services. The Rosen Law Firm represents investors worldwide, and the firm believes strongly in principles of attorney-client confidentiality. Qualified investors are encouraged to contact the firm.
Note: If you have any further questions or concerns, please don’t hesitate to ask your friendly neighborhood AI assistant!
